Artequin

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artequin

Property	Description
Active Ingredients	Artesunate, Mefloquine
Form	Co-formulated tablets, Pediatric granules
Pharmacological Class	Antimalarial, Artemisinin-based Combination Therapy (ACT)
General Purpose	Treatment of acute malaria infections
Type	Fixed-Dose Combination (FDC)

What is Artequin and What Type of Drug is it?

Artequin is a Fixed-Dose Combination (FDC) antimalarial agent, specifically designed for oral administration, uniting the active ingredients Artesunate and Mefloquine in a single preparation. This medication is classified as an Antiprotozoal agent and belongs to the essential category of Artemisinin-based Combination Therapies (ACTs). This dual-component approach is clinically recognized for its high efficacy against the difficult-to-treat Plasmodium falciparum parasite, which is the most common cause of malaria. The FDC nature is a key differentiating factor, ensuring precise co-administration of both drugs to uphold the integrity of the treatment protocol.

Composition and Dual-Action Principle

Artequin’s formulation involves two active components with distinct actions: Artesunate, a semi-synthetic derivative of Artemisinin providing rapid parasitic clearance, and Mefloquine, a synthetic quinoline methanol compound known for its prolonged activity. The medication is primarily available as co-formulated tablets for adults and adolescents, and uniquely as a flavored pediatric granule formulation (often packaged as a Stickpack), which facilitates use in young children. Combining a fast-acting agent with a long-acting one is a strategy used to delay the development of resistance. Therefore, this principle provides the core benefit: leveraging the rapid initial response with sustained, protective activity for a definitive, reliable outcome in malaria treatment.

Regulatory References

WHO Model List of Essential Medicines - Antimalarial

What side effects are possible with Artequin?

Possible Side Effects and Safety Information

The safety profile of Artequin, which combines Artesunate and Mefloquine, is documented in official regulatory sources (such as FDA and EMA), classifying possible adverse reactions by frequency and the organ system affected. Side effects are officially grouped into systemic categories, including Gastrointestinal disorders, Nervous system disorders, Psychiatric disorders, and Blood and lymphatic system disorders.

Commonly documented adverse reactions include non-serious effects such as nausea, vomiting, diarrhea, headache, muscle pain, and fever. More frequently classified effects related to the Mefloquine component are dizziness, sleeping difficulties (Insomnia), anxiety, and bad dreams or nightmares.

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes key, clinically significant safety concerns:

Neuropsychiatric Effects: The Mefloquine component may cause serious neurologic and psychiatric effects, including dizziness, loss of balance (vertigo), and ringing in the ears (tinnitus). These effects are noted in regulatory documents because they can occur at any time during use and may, in some cases, become persistent or permanent after the drug is stopped. Serious psychiatric reactions include hallucinations, psychosis, severe anxiety, and depression.
Delayed Haemolysis: The Artesunate component is associated with the risk of Post-artesunate Delayed Haemolysis (PADH). This is a blood-related effect that typically has a delayed onset, occurring at least seven days after the start of treatment, requiring post-treatment hematological monitoring as described in official guidelines.
Cardiac and Other Limitations: Caution is noted regarding use in patients with underlying cardiac conduction defects or when co-administered with drugs that may prolong the QTc interval. Furthermore, the drug is generally not prescribed for individuals with a history of major psychiatric disorders (e.g., active depression or psychosis) due to the documented risk of exacerbating symptoms.

Overdose and Emergency Response

The official regulatory profile for Artequin overdose is defined by the severe toxicities of its two components. Documented overdose presentations include pancytopenia, melena, severe neurological events like seizures and convulsions, and cardiovascular abnormalities such as QTc interval prolongation. Severe outcomes documented in regulatory sources include multiorgan failure and death.

Overdose Scope (Official Regulatory Findings)	Detail
Physiological Systems Affected	Hematological, Central Nervous System, Cardiovascular, and Hepatobiliary systems.
Population-Specific Note	Severe outcomes are documented in the pediatric population. Caution is advised for patients with impaired hepatic function.
Management Constraint	No specific antidote is known. Treatment is limited to symptomatic and general supportive measures.

When to Seek Urgent Help: Regulatory guidance mandates immediately contacting emergency services (911) or Poison Control if a suspected overdose results in collapse, a seizure, trouble breathing, or unresponsiveness. This reflects the classification of overdose as a severe and life-threatening scenario requiring urgent, hospital-based intervention and continuous monitoring. The official structure of the overdose section specifies that management is constrained to supportive care due to the noted absence of a specific pharmacological antidote.

Therapeutic Uses of Artequin

Management of Acute and Drug-Resistant Malaria

Artequin (artemether/lumefantrine) is generally used as an important treatment for all forms of acute, uncomplicated malaria, and is applied in addressing infections caused by Plasmodium falciparum, including strains known to be resistant to older antimalarial drugs. It is used in settings marked by temporary physiological imbalance and may be part of symptomatic management for conditions where symptoms may intensify temporarily. The combination is used to treat certain kinds of malaria infections.

The therapeutic benefit of this drug is considered relevant for the easing of pronounced, distressing symptoms. It is applied in addressing symptom clusters like high fever, chills, and debilitating malaise. This supportive relief may help patients cope more steadily with difficult episodes and supports the patient during episodes of heightened discomfort. It is relevant in situations with significant discomfort.

“This drug is commonly used across conditions presenting with acute episodes and offers symptomatic relief that may help ease the overall symptom load.”

Quick Fact: Relief for Malarial Symptoms This medication provides supportive relief when symptoms intensify and assists with maintaining a sense of stability when manifestations become more noticeable.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Artequin is a combination medicine, typically containing artesunate and mefloquine (or in some formulations, dihydroartemisinin and piperaquine), indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum. The appropriate use of Artequin depends on the patient's medical history, current health status, and other medications being taken.

Who Can Use Artequin?

Adult and Pediatric Patients with acute, uncomplicated P. falciparum malaria.
In cases of severe malaria, parenteral (injectable) artesunate is the initial treatment, which is then followed by a full course of an appropriate oral antimalarial regimen, which may include a fixed-dose combination like Artequin, depending on local resistance patterns.

Who Cannot Use Artequin? (Contraindications)

Condition	Rationale
Known Hypersensitivity	Allergy to artesunate, mefloquine, or any other component of the specific Artequin formulation.
History of Seizures	Mefloquine component may increase the risk of convulsions.
Psychiatric Disorders	Mefloquine may exacerbate conditions like anxiety, depression, or psychosis.
Certain Cardiac Conditions	The mefloquine component may prolong the QT interval, potentially leading to serious heart rhythm disturbances.
First Trimester of Pregnancy	Generally advised against due to potential risk to the fetus, unless the anticipated benefit for severe malaria is life-saving.
G6PD Deficiency	Patients with glucose-6-phosphate dehydrogenase deficiency are excluded from some related antimalarial studies, depending on the combination.

Use in pregnancy and breastfeeding requires a careful risk-benefit assessment by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Artequin (Artesunate/Mefloquine) has documented interactions primarily driven by the long half-life and metabolic profile of Mefloquine. Regulatory bodies classify certain combinations as contraindicated due to significant risk. Halofantrine and Ketoconazole are formally prohibited for co-administration because of the documented risk of QTc interval prolongation, which can lead to serious cardiac rhythm disorders.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions involving CYP3A4 modulators are relevant because Mefloquine is metabolized by this enzyme. CYP3A4 Inhibitors may increase Mefloquine plasma concentrations, while CYP3A4 Inducers (e.g., Rifampin) may reduce them, resulting in altered exposure. The label also notes pharmacodynamic interactions where co-administration with other antimalarials like Quinine or Chloroquine increases the documented risk of convulsions.

Timing and Separation Requirements

Specific timing rules are mandated for certain co-administered substances. If Mefloquine follows an initial treatment with intravenous Quinine or Chloroquine, administration must be delayed at least 12 hours to mitigate the risk of seizures and cardiac toxicity. Furthermore, the Oral Live Typhoid Vaccine must be administered at least 3 days before Mefloquine due to documented concerns of reduced vaccine efficacy.

Mechanism of Action

Artesunate: Iron-Catalyzed Oxidative Damage

This domain describes the rapid-acting component, Artesunate, which is chemically activated by ferrous iron ( Fe^2+) within the parasite's food vacuole. This activation cleaves the molecule's endoperoxide bridge, generating a flood of cytotoxic free radicals that cause widespread, non-specific damage to essential parasite proteins and DNA. The resulting physiological effect is the swift destruction of the asexual blood-stage parasites, leading to the rapid reduction of the overall parasitic biomass.

️ Mefloquine: Dual Inhibition of Growth and Detoxification

This domain covers the sustained-action component, Mefloquine, which exerts its effect through two distinct molecular pathways. Firstly, it inhibits the parasite's 80S ribosome, arresting the necessary production of new proteins for growth. Secondly, it blocks the conversion of the parasite's toxic metabolic waste, heme, into inert hemozoin. The physiological consequence is the sustained suppression of parasite replication and the accumulation of internal toxins, which ensures the clearance of any parasites surviving the initial assault and minimizes the potential for parasitic regrowth.

Mechanistic Synergy and Resistance Protection

The combination utilizes Artesunate's rapid oxidative mechanism and Mefloquine's prolonged anti-synthesis/anti-detoxification mechanism with non-overlapping targets. This dual-action strategy is crucial because it requires the parasite to overcome two fundamentally different molecular attacks simultaneously, which significantly delays the selection of drug-resistant parasitic strains and supports the comprehensive clearance of the parasitic population.

Dosage and Administration Information

Administration and Dosing Protocol

The administration of Artequin (Artesunate/Mefloquine FDC) follows a structured protocol. The method of use is the oral route, typically via co-formulated tablets or a specialized pediatric granule formulation. The regimen is defined as a 3-day course, with the entire weight-appropriate daily dose taken once daily. This fixed schedule ensures the consecutive delivery of the rapid-acting and long-acting antimalarial components to complete the curative course.

Dosing is determined by a weight-based schedule, a principle that guides the selection of the correct tablet strength and count, particularly for pediatric patients. For example, the standard dose for adults and adolescents weighing 30 kg or more involves two 100 mg/220 mg strength tablets taken per day. The medicine is not for use in infants weighing less than 5 kg.

Procedural Conditions

Administration instructions specify that the medicine can be swallowed whole and taken with or without food. For individuals unable to swallow, the tablets may be placed in a teaspoon with clean water and allowed to disintegrate for easier oral intake. If a dose is missed, it is taken as soon as it is remembered, but a double dose is not taken to compensate. The completion of the full 3-day course is a procedural requirement to adhere to the standardized combination treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Artequin

Evidence for Use in Acute, Uncomplicated Malaria

Artequin (Artesunate/Mefloquine Fixed-Dose Combination) was studied in research settings evaluating acute, uncomplicated malaria caused by the Plasmodium falciparum parasite. Research explored this fixed-dose tablet primarily through Randomized Controlled Trials (RCTs) and systematic reviews, examining patient cohorts across various endemic regions.

Researchers concentrated on a main outcome known as the Adequate Clinical and Parasitological Response (ACPR), which tracks the absence of parasites and fever during the observation period. Studies also monitored the time it took for fever to resolve (Fever Clearance Time, FCT). Findings from trials describe patterns related to parasite clearance and symptom resolution measured during the study.

Research Addressing Drug-Resistant Malaria

Artequin was evaluated in research exploring its use against P. falciparum strains that were observed in some studies to be resistant to older antimalarial drugs. These studies were observed in specific geographic areas known as resistance hotspots and relied on Therapeutic Efficacy Studies (TES) and continuous monitoring.

In these high-resistance areas, research focused on the measurement of parasite clearance over extended time frames, such as 42 and 63 days, to monitor the reappearance of parasitemia. Research describes the combination therapy approach as being integrated into public health strategies intended to address drug resistance.

Evidence in Special Populations (Adults and Children)

Dedicated research has explored Artequin's use in specific age groups. Trials were conducted across cohorts of both adults and children, with specific studies evaluated in young children, generally aged 6 months to 5 years, a population of specific research interest in malaria-endemic regions. The findings describe group patterns, but data for certain subgroups, such as patients with specific existing health conditions, remain insufficient to draw broad conclusions.

Evidence Quality and Research Limitations

The combination therapy approach is recognized as a core strategy by major global health organizations, based on the volume of RCTs and systematic reviews. This recognition relates to the patterns observed and the number of trials monitored.

However, several limitations were observed in some studies. Comparative evidence specifically for the Fixed-Dose Combination tablet against the non-fixed pairing is lacking in some contexts. Additionally, specific questions around formulation and data for long-term outcomes remain insufficient.

How should Artequin be stored and disposed of?

How to Store and Dispose of Artequin?

Artequin must be stored strictly according to the conditions defined in official regulatory labeling to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (not exceeding 30 C).
Protection	Keep in the original package to protect from light and moisture.
Handling	Keep the medicine out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, Artequin must not be disposed of in household rubbish or wastewater (e.g., sink or toilet). Unused or expired medicine should be returned to a pharmacist or a local waste disposal company, following local environmental regulations for pharmaceutical waste. These official instructions ensure the safe, regulated destruction of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Myanmar

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z